Page 3 - Jeffrey Meckler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeffrey meckler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeffrey Meckler Today - Breaking & Trending Today

Indaptus Therapeutics Inc. (via Public) / Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference

Indaptus Therapeutics Inc. (via Public) / Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

Jeffrey Meckler , Exchange Commission , Maxim Group , Indaptus Therapeutics To Present At Maxim Group , Indaptus Therapeutics Inc , Indaptus Therapeutics , Growth Conference , Chief Executive Officer , Investor Relations , Private Securities Litigation Reform , Annual Report , Indaptus Therapeutics Inc Via Public To Present At Maxim Group 2022 Virtual Growth Conference ,

Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces the appointment of Mark Gilbert, M.D., to its Board of Directors. ....

United States , San Francisco , Phil Greenberg , Jeffrey Meckler , Hoonmo Lee , Mark Gilbert , University Of California , Indaptus Therapeutics Inc , Celgene Corporation , University Of Iowa , University Of Iowa Medical School , Bayer Schering Pharmaceuticals , University Of Washington , Berlex Pharmaceuticals , Fred Hutchinson Cancer Research Center , Chief Medical Officer , Juno Therapeutics , Executive Vice President , Director Hoonmo Lee , Indaptu Board , Indaptus Board , Chief Executive Officer , Senior Management , Iowa Medical , Private Securities Litigation Reform , Willo Connor ,

Intec Closes Merger with Decoy Biosystems

Intec Closes Merger with Decoy Biosystems
USA - English
Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus
News provided by
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Indaptus Therapeutics, Inc. (Nasdaq: INDP) ( Indaptus or the Company, and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ( Decoy ) and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company s therapeutic focus.
Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol INDP and a new CUSIP number (45339J 105). The previous ticker symbol was NTEC (Nasdaq: NTEC). The Company will have a new website address: www.indaptusrx.com. ....

Jeffrey Meckler , Anthonyj Maddaluna , Hoonmo Lee , Hila Karah , Wintec Pharma , Roger Pomerantz , Brian Ocallaghan , Michaelj Newman , Nir Sassi , Walt Linscott , Jeffreya Meckler , Michael Newman , Williamb Hayes , Intec Parent Inc , Indaptus Therapeutics Inc , Prnewswire Indaptus Therapeutics Inc , Exchange Commission , Intec Pharma Ltd , Securities Exchange , Nasdaq Stock Market , Decoy Biosystems Inc , Hc Wainwright Co , Intec Parent , Decoy Biosystems , Indaptus Therapeutics , Nasdaq Capital Market ,

Intec Pharma and Decoy Biosystems Announce Merger Agreement

Intec Pharma and Decoy Biosystems Announce Merger Agreement
USA - English
Investigational New Drug Application Filing Expected in 2H 2021
News provided by
Share this article
Share this article
JERUSALEM, March 15, 2021 /PRNewswire/ Intec Pharma Ltd. (NASDAQ: NTEC) ( Intec or the Company ) announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses.
The combined company will advance its immunotherapy platform to battle a variety of tumor types and chronic viral infections. Decoy previously held a pre-IND meeting with the FDA, currently plans to file an IND in the second half of 2021 and to initiate a Phase I clinical trial in 2022 targeting solid tumors and lymphomas. ....

Israel General , San Diego , United States , Wintec Pharma , Roger Pomerantz , Har Hotzvim , Michaelj Newman , Jeffreya Meckler , Prnewswire Intec Pharma Ltd , Intec Pharma Ltd , Company Current Report On Form , Decoy Biosystems Inc , Company Accordion Pill , Decoy Biosystems , Vice Chairman , Chief Executive Officer , Accordion Pill , Jeffrey Meckler , Michael Newman , Chief Scientific Officer , Johnson Innovation , Investor Relations , Proposed Merger , Registration Statement , Decoy Biosystem , Annual Report ,